Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$242.43 +1.5%	$254.71	$141.98 ▼ $304.39	$31.38B	0.39	790,683 shs	592,953 shs
BIIB Biogen	$140.19 -2.4%	$143.55	$128.51 ▼ $238.00	$20.52B	0.01	1.56 million shs	1.95 million shs
EXEL Exelixis	$37.20 +0.7%	$35.25	$20.14 ▼ $40.02	$10.41B	0.57	2.09 million shs	2.75 million shs
UTHR United Therapeutics	$307.09 +0.9%	$351.85	$221.53 ▼ $417.82	$13.79B	0.64	446,129 shs	723,336 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.55%	-2.73%	-11.54%	-1.15%	+65.31%
BIIB Biogen	-2.42%	-2.49%	-1.65%	-9.75%	-38.34%
EXEL Exelixis	+0.73%	-3.75%	+11.04%	+5.74%	+63.95%
UTHR United Therapeutics	+0.88%	-1.25%	-11.15%	-15.08%	+24.39%

Remove Ads

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.5772 of 5 stars	4.4	2.0	4.3	3.3	2.5	0.6
BIIB Biogen	4.7911 of 5 stars	4.2	3.0	3.7	3.3	2.5	1.9
EXEL Exelixis	4.1312 of 5 stars	2.3	1.0	4.3	2.1	2.5	3.1
UTHR United Therapeutics	4.8413 of 5 stars	3.3	2.0	4.6	3.5	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.72	Moderate Buy	$304.26	25.50% Upside
BIIB Biogen	2.43	Hold	$213.33	52.17% Upside
EXEL Exelixis	2.50	Moderate Buy	$37.24	0.09% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$388.25	26.43% Upside

Current Analyst Ratings Breakdown

Latest EXEL, ALNY, BIIB, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/11/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$272.00 ➝ $280.00
2/27/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00
2/26/2025	ALNY Alnylam Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/26/2025	ALNY Alnylam Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$310.00 ➝ $310.00
2/26/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00
2/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
2/24/2025	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$400.00 ➝ $500.00
2/24/2025	EXEL Exelixis	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$36.00 ➝ $36.00
2/18/2025	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$384.00 ➝ $385.00
2/18/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$138.00 ➝ $135.00
2/14/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$310.00 ➝ $300.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	13.96	N/A	N/A	$0.52 per share	466.21
BIIB Biogen	$9.68B	2.12	$23.02 per share	6.09	$114.71 per share	1.22
EXEL Exelixis	$2.17B	4.80	$2.04 per share	18.22	$8.02 per share	4.64
UTHR United Therapeutics	$2.88B	4.79	$18.47 per share	16.63	$127.35 per share	2.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.17	N/A	272.39	N/A	-12.37%	N/A	-6.83%	5/1/2025 (Estimated)
BIIB Biogen	$1.63B	$11.19	12.53	8.49	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
EXEL Exelixis	$521.27M	$1.77	21.02	14.59	1.13	24.04%	23.52%	17.95%	4/3/2025 (Confirmed)
UTHR United Therapeutics	$984.80M	$24.60	13.49	11.17	0.97	40.31%	19.22%	16.15%	5/7/2025 (Estimated)

Latest EXEL, ALNY, BIIB, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/26/2025	Q4 24	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/13/2025	Q4 2024	ALNY Alnylam Pharmaceuticals	-$0.62	-$0.65	-$0.03	-$0.65	$580.62 million	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/11/2025	Q4 2024	EXEL Exelixis	$0.51	$0.48	-$0.03	$0.48	$563.23 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BIIB Biogen	0.27	1.35	0.90
EXEL Exelixis	N/A	3.63	3.58
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
EXEL Exelixis	85.27%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BIIB Biogen	0.16%
EXEL Exelixis	2.85%
UTHR United Therapeutics	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	129.46 million	127.52 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
EXEL Exelixis	1,147	279.88 million	271.90 million	Optionable
UTHR United Therapeutics	980	44.91 million	39.33 million	Optionable

EXEL, ALNY, BIIB, and UTHR Headlines

Recent News About These Companies

Wealthfront Advisers LLC Acquires 18,313,424 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 12 at 6:56 AM | marketbeat.com

Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update

March 11 at 11:10 PM | seekingalpha.com

United Therapeutics Co. (NASDAQ:UTHR) Stake Raised by AlphaQuest LLC

March 11 at 4:38 AM | marketbeat.com

918 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Callan Family Office LLC

March 11 at 4:02 AM | marketbeat.com

Ruffer LLP Invests $4.04 Million in United Therapeutics Co. (NASDAQ:UTHR)

March 10 at 7:55 AM | marketbeat.com

Edgestream Partners L.P. Boosts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

March 10 at 4:33 AM | marketbeat.com

Ashton Thomas Private Wealth LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

March 10 at 4:33 AM | marketbeat.com

Andra AP fonden Purchases 5,500 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 8, 2025 | marketbeat.com

Candriam S.C.A. Grows Position in United Therapeutics Co. (NASDAQ:UTHR)

March 7, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Victory Capital Management Inc.

March 7, 2025 | marketbeat.com

Seizert Capital Partners LLC Acquires 1,312 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 5, 2025 | marketbeat.com

Assetmark Inc. Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

March 5, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Lifted by Fisher Asset Management LLC

March 5, 2025 | marketbeat.com

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

March 4, 2025 | finance.yahoo.com

Westover Capital Advisors LLC Invests $679,000 in United Therapeutics Co. (NASDAQ:UTHR)

March 4, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Oppenheimer & Co. Inc.

March 4, 2025 | marketbeat.com

Leerink Partnrs Issues Pessimistic Outlook for UTHR Earnings

March 4, 2025 | americanbankingnews.com

LGT Fund Management Co Ltd. Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

March 3, 2025 | marketbeat.com

Q2 EPS Estimate for United Therapeutics Lowered by Analyst

March 3, 2025 | marketbeat.com

Q1 Earnings Forecast for UTHR Issued By HC Wainwright

March 3, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Poplar Forest Capital LLC

March 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
By Gabriel Osorio-Mazilli | February 14, 2025
View NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
Biogen Stock Is Mutating Into a Value Play
By Jea Yu | February 20, 2025
View Biogen Stock Is Mutating Into a Value Play
2 Safe-Haven Stocks Shielded From Import Tariffs
By Jea Yu | February 25, 2025
View 2 Safe-Haven Stocks Shielded From Import Tariffs

EXEL, ALNY, BIIB, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$242.43 +3.69 (+1.55%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$242.95 +0.52 (+0.21%)

As of 03/12/2025 06:51 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$140.19 -3.47 (-2.42%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$140.82 +0.63 (+0.45%)

As of 03/12/2025 07:40 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Exelixis NASDAQ:EXEL

$37.20 +0.27 (+0.73%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$37.03 -0.17 (-0.46%)

As of 03/12/2025 06:47 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

United Therapeutics NASDAQ:UTHR

$307.09 +2.67 (+0.88%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$307.10 +0.01 (+0.00%)

As of 03/12/2025 05:48 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time